| Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers (NCT04886531) | Ruth O'Regan | 2022-07-21 |
| TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain Metastases (NCT04512261) | Reva Basho | 2022-06-01 |
| Novel Double Target Therapy Combined With Chemotherapy in First-line Treatment of HER2+ Breast Cancer, MA-BC-II-038 (NCT05429294) | First Affiliated Hospital Xi'an Jiaotong University | 2022-06-01 |
| Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer (NCT05378464) | H. Lee Moffitt Cancer Center and Research Institute | 2022-05-31 |
| Asian Multicenter Prospective Study in HER2 Positive Early Breast Cancer for Detecting MRD by ctDNA;HARMONY Study (NCT05433753) | National Cancer Center, Japan | 2022-05-24 |
| A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients (NCT05426486) | Caigang Liu | 2022-05-23 |
| Tucatinib in Patients With Locally Advanced or Metastatic HER2-positive Breast Cancer Who Received at Least Two Prior Anti-HER2 Treatment Regimens. (NCT05253911) | iOMEDICO AG | 2022-05-21 |
| Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer (NCT05227131) | MedSIR | 2022-05-15 |
| A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer (NCT05474690) | Henan Cancer Hospital | 2022-05-11 |
| PIK3CA in HER2+ BC and pCR Trial (NCT05750693) | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 2022-05-02 |
| DP303c in Patients With HER2-positive Unresectable Locally Advanced, Relapsed, or Metastaticbreast Cancer (NCT05334810) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2022-05-01 |
| 99mTc-DARPinG3-based HER2 Expression Molecular Imaging in HER2-positive Breast Cancer During Chemo+Targeted Therapy (NCT05412459) | Tomsk National Research Medical Center of the Russian Academy of Sciences | 2022-05-01 |
| A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer (NCT05346224) | Shanghai Henlius Biotech | 2022-04-25 |
| Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI (NCT04332588) | University of Alabama at Birmingham | 2022-03-25 |
| A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer (NCT05132582) | Seagen, a wholly owned subsidiary of Pfizer | 2022-03-07 |
| A Trial of Eribulin in Combination With HP Neoadjuvant Therapy in Patients With for HER2-Positive BC (NCT05945368) | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2022-02-25 |
| A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers (NCT05091528) | Silverback Therapeutics | 2022-02-08 |
| Efficacy and Safety of Adjuvant Docetaxel and Trastuzumab in Stage I HER2-positive Breast Cancer (NCT05189067) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2022-01-31 |
| De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 Blockade (NCT04675827) | Jules Bordet Institute | 2022-01-17 |
| Neratinib Dose Escalation Regimen for HER2 Positive Early Breast Cancer (NCT05154396) | Chinese Academy of Medical Sciences | 2022-01-01 |
| Programmed Death-Ligand1 Expression in Her-2 Positive and Triple Negative Breast Cancer (NCT05169853) | Ain Shams University | 2022-01-01 |
| Study of Screening Brain MRIs in Stage IV Breast Cancer (NCT05115474) | H. Lee Moffitt Cancer Center and Research Institute | 2021-12-21 |
| Identification of Genetic Determinants for Treatment Resistance/Sensitivity and/or Toxicity in Adjuvant Setting for HER2 Positive Breast Cancer (NCT04638725) | Centre Paul Strauss | 2021-12-15 |
| HER2-directed Biosimilar in Breast Cancer: Real World ePRO (NCT05234021) | OnkoZentrum Zürich AG | 2021-12-14 |
| Safety, Effectiveness and Quality of Life of Trastuzumab Deruxtecan in Patients with HER2+ Breast Cancer (NCT05149014) | Daiichi Sankyo France | 2021-12-14 |
| RC48 for Neoadjuvant Chemotherapy of HER2 Positive Breast Cancer (NCT05134519) | Xijing Hospital | 2021-11-26 |
| Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab (NCT05325632) | H. Lee Moffitt Cancer Center and Research Institute | 2021-10-28 |
| Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast Cancer (NCT05076695) | Fudan University | 2021-10-15 |
| Cardiotoxicity of Targeted Therapy for HER-2 Positive Breast Cancer Patients at High Altitude (NCT05063643) | Affiliated Hospital of Qinghai University | 2021-10-01 |
| TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN) (NCT04760431) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2021-10-01 |
| Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab (NCT05346861) | Fudan University | 2021-09-15 |
| Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases (NCT04899908) | Brigham and Women's Hospital | 2021-09-15 |
| Study of Cardiopulmonary Exercise Testing in Women Who Have HER2-Positive Breast Cancer With Mild Cardiotoxicity (NCT05036252) | Memorial Sloan Kettering Cancer Center | 2021-08-27 |
| ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer (NCT04602117) | QuantumLeap Healthcare Collaborative | 2021-07-28 |
| Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label (NeoON) (NCT05036005) | Institut fuer Frauengesundheit | 2021-07-11 |
| ATEMPT 2.0: Adjuvant T-DM1 vs TH (NCT04893109) | Dana-Farber Cancer Institute | 2021-06-16 |
| Pyrotinib Combined With Trastuzumab for Maintenance Therapy After First-line TH (P) Therapy for HER2+ABC (NCT06754059) | zhangjie | 2021-06-01 |
| Exosome as the Prognostic and Predictive Biomarker in EBC Patients (NCT05955521) | Samsung Medical Center | 2021-05-01 |
| Early On-treatment Transcriptional Profiling as Predictor of Response in Early-stage HER2-positive Breast Cancer (NCT05912062) | Institut Català d'Oncologia | 2021-03-22 |
| Investigating the Long-term Cardiac Sequelae of Trastuzumab Therapy (NCT05019365) | University of Glasgow | 2021-03-15 |
| Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers (NCT04464967) | NKGen Biotech, Inc. | 2021-03-01 |
| Circulating Tumor Cells and Treatment De-escalation After Neoadjuvant Therapy for HER2 Positive Breast Cancer (NCT04993014) | AC Camargo Cancer Center | 2021-03-01 |
| CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors (NCT04660929) | Carisma Therapeutics Inc | 2021-02-02 |
| A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer (NCT04569747) | Dana-Farber Cancer Institute | 2021-01-11 |
| Tumor Markers for Efficacy of Dual-Target Therapy in HER2+ Breast Cancer (NCT07115095) | Nanlin Li | 2021-01-01 |
| Pyrotinib Combined With Trastuzumab And Chemotherapy in HER2-positive MBC (NCT04609540) | Shandong Cancer Hospital and Institute | 2021-01-01 |
| Pyrotinib, Trastuzumab And Abraxane in HER2-positive MBC With Brain Metastasis (NCT04639271) | Shandong Cancer Hospital and Institute | 2021-01-01 |
| Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease (NCT04588545) | H. Lee Moffitt Cancer Center and Research Institute | 2020-12-10 |
| Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors (NCT04650451) | Bellicum Pharmaceuticals | 2020-12-07 |
| A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer (NCT04539938) | Seagen, a wholly owned subsidiary of Pfizer | 2020-12-01 |
| CT-based Radiomics of ALN pCR (ypN0) in Breast Cancer Undergoing NAC (NCT04457700) | Peking University | 2020-11-01 |
| The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (NCT04585750) | PMV Pharmaceuticals, Inc | 2020-10-29 |
| Clinical Study to Evaluate the Efficacy and Safety of TQB2440 Injection/Perjeta® Combined With Trastuzumab and Docetaxel in the Treatment of Patients With Early or Locally Advanced Breast Cancer. (NCT05985187) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2020-10-20 |
| Trial of ZN-A-1041 Enteric Capsules in Patients With HER2-Positive Advanced Solid Tumors (NCT04487236) | Suzhou Zanrong Pharma Limited | 2020-10-15 |
| Omission of Surgery in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti-HER2-based Neoadjuvant Therapy (NCT04578106) | Fundacio Clinic Barcelona | 2020-09-23 |
| The Use of FES-PET Imaging as a Tool to Detect a Possible Reversion of Estrogen Receptor (ER)-α Status in Patients With Metastatic Breast Cancer HER2 + and ERα Neg Treated With Trastuzumab + Pertuzumab + Taxane. (NCT03619044) | Institut Claudius Regaud | 2020-08-28 |
| PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer (NCT04360941) | Royal Marsden NHS Foundation Trust | 2020-08-11 |
| TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer (NCT04246671) | Bavarian Nordic | 2020-08-10 |
| MARGetuximab Or Trastuzumab (MARGOT) (NCT04425018) | Dana-Farber Cancer Institute | 2020-07-13 |
| Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors (NCT04450732) | GeneQuantum Healthcare (Suzhou) Co., Ltd. | 2020-07-07 |
| Trastuzumab Combined With Pyrrolidine and Chemotherapy for Locally HER2 Positive Breast Cancer (NCT04481932) | Peking University | 2020-07-01 |
| Anti-HER2 Therapy + Fulvestrant/Capecitabine in Women With HR+, HER2+, Non-visceral Metastases Stage IV Breast Cancer (NCT04337658) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2020-07-01 |
| Parsaclisib in Newly Diagnosed Stage I-IIIC Triple Negative or HER2+ Breast Cancer (NCT04142554) | UNC Lineberger Comprehensive Cancer Center | 2020-06-01 |
| Real World Study on the Efficacy and Safety of Anti-HER2 Therapy (NCT05367739) | Hunan Cancer Hospital | 2020-06-01 |
| Adjuvant Dual Anti-HER2 Therapy in Patients With Small, Node-negative, HER2-positive Breast Cancer (NCT04158856) | xuexin he | 2020-06-01 |
| DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease (NCT04420598) | MedSIR | 2020-05-25 |
| Markers to Evaluate the Efficacy of PH-based Regimen as a Neoadjuvant Therapy for Operable HER2 Positive Breast Cancer (NCT04281641) | Fudan University | 2020-04-21 |
| Real World Study of Pyrotinib in Human Epidermal Growth Factor Receptor-2 (HER2) Positive Breast Cancer (NCT04158505) | Chinese Academy of Medical Sciences | 2020-02-28 |
| A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors (NCT04278144) | Bolt Biotherapeutics, Inc. | 2020-02-24 |
| A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer. (NCT04236310) | Ruijin Hospital | 2020-01-15 |
| Pyrotinib Combined With Brain Radiotherapy in Breast Cancer Patients With Brain Metastases (NCT04582968) | Fudan University | 2020-01-02 |
| Avoiding Sentinel Lymph Node Biopsy in Breast Cancer Patients After Neoadjuvant Chemotherapy (NCT04225858) | The Netherlands Cancer Institute | 2020-01-01 |
| PLD-cyclophosphamide-Nab-P Continuously Combined With Dual HER2 Blockage for HER2-positive Breast Cancer (NCT05346107) | Xijing Hospital | 2020-01-01 |
| A Study to Measure the Expression of the HER2-HER3 Dimer in Tumour and Blood (Exosomes) Samples From Patients With HER2 Positive Breast Cancer Receiving HER2 Targeted Therapies (NCT04288141) | King's College London | 2019-12-20 |
| Phase II Study of Herzuma® Plus Gedatolisib in Patients With HER-2 Positive Metastatic Breast Cancer (NCT03698383) | Korean Cancer Study Group | 2019-12-03 |
| Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer (NCT03879577) | University of Chicago | 2019-11-25 |
| fREEDOM: REsonance for Early Detection Of Breast Cancer Metastases (NCT06328465) | European Institute of Oncology | 2019-11-22 |
| Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer (NCT04042051) | Cancer Trials Ireland | 2019-11-12 |
| Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer (NCT04088110) | Fuzhou General Hospital | 2019-11-01 |
| A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer (NCT03975647) | Seagen, a wholly owned subsidiary of Pfizer | 2019-10-02 |
| A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer (NCT04095390) | Jinming Yu | 2019-09-30 |
| TCHP Versus EC -THP as Neoadjuvant Treatment for HER2-Positive Breast Cancer (NCT04094896) | Guangdong Provincial People's Hospital | 2019-09-17 |
| KN035 in Combination With Trastuzumab and Docetaxel in HER2-positive Breast Cancer (NCT04034823) | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2019-09-01 |
| Extension Study to Provide Adjuvant Treatment Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03 (NCT04109391) | Tanvex BioPharma USA, Inc. | 2019-08-20 |
| Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer (NCT03981705) | Masonic Cancer Center, University of Minnesota | 2019-08-08 |
| Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer (NCT04030507) | Brigham and Women's Hospital | 2019-07-26 |
| Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast (NCT03812393) | West Cancer Center | 2019-06-21 |
| Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy (NCT04106167) | Fate Therapeutics | 2019-06-11 |
| Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC (NCT03910712) | Peking Union Medical College Hospital | 2019-06-01 |
| TAHP for Patients With HER2-positive Early Breast Cancer and Subsequent AHP Adjuvant tHerapy After Surgery (NCT03881878) | Samsung Medical Center | 2019-05-27 |
| Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer (NCT03894007) | Renske Altena | 2019-05-23 |
| Pyrotinib in Combination With Nab-paclitaxel in Patients With HER2-positive Advanced Breast Cancer: an Exploratory Study (NCT03919253) | Hebei Medical University Fourth Hospital | 2019-04-30 |
| To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH) (NCT03644186) | ETOP IBCSG Partners Foundation | 2019-04-16 |
| Neoadjuvant Nab-paclitaxel in Triple-negative or HER2-positive Breast Cancer (NCT03907800) | Ruijin Hospital | 2019-04-01 |
| B003 in Patients With HER2-positive Recurrent or Metastatic Breast Cancer (NCT03953833) | Shanghai Pharmaceuticals Holding Co., Ltd | 2019-04-01 |
| Phase Ⅱ Study of Pegylated Liposomal Doxorubicin（PLD）Plus Trastuzumab in HER-2 Positive Metastatic Breast Cancer (NCT03933319) | Chinese Academy of Medical Sciences | 2019-03-11 |
| Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Chemotherapy in Patients With HER2 Positive Breast Cancer (NCT03847818) | Shandong University | 2019-03-01 |
| FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors (NCT03841110) | Fate Therapeutics | 2019-02-15 |
| Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP] (NCT03747120) | University of Texas Southwestern Medical Center | 2019-01-25 |
| Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1 (NCT03630809) | H. Lee Moffitt Cancer Center and Research Institute | 2019-01-10 |